Marta Figueiredo, PhD,  science writer—

Ascendis Pharma’s investigational therapy TransCon PTH safely restored calcium and phosphate balance and eliminated the need for current standard care in adults with hypoparathyroidism, top-line data from a Phase 2 clinical trial show. “With TransCon PTH, our goal has always been to improve the lives of patients…

Long-term treatment with Takeda’s parathyroid hormone therapy Natpara normalizes bone remodeling and bone density in people with hypoparathyrodism, according to a four-year study. This is the longest study of Natpara’s effects on bone structure in this patient population, as assessed with a non-invasive method called high…

The injection of carbon nanoparticles during surgery to remove thyroid cancer and central lymph nodes is helpful to protect the parathyroid glands from damage and prevent temporary hypoparathyroidism, a recent study suggests. The study, “Short and Long-Term Potential Role of Carbon Nanoparticles in Total Thyroidectomy with Central…

Shire plans a Phase 4 clinical trial of its parathyroid hormone therapy Natpara as an add-on to standard hypothyroidism treatment. Hypoparathyroidism is caused by abnormal low levels of parathyroid hormone (PTH), which regulates levels of calcium in blood and bones. Low levels of the hormone lead to a  mineral imbalance that…